PALI
Palisade Bio, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Palisade Bio (PALI) Stock: Buy, Sell, or Hold?
$1.15
-0.02 (-2.14%)
▼
5d:
-1.29%
30d:
-22.64%
90d:
-46.5%
QUANTITATIVE VERDICT
HOLD
LOW Confidence (95%)
Quality Score
62/100
Position
OVERSOLD
30-Day Fair Range
$1.18 – $1.47
Position: OVERSOLD
Forward P/E & Valuation
-4.1x
Next 12M consensus est.
Wall Street Target
$8.90
+660.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.08 / $1.30
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: PALI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
Get Alerted When PALI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: PALI is currently trading at $1.15, which is considered oversold relative to its 30-day fair value range of $1.18 to $1.47.
Technical Outlook: Technically, PALI is in a strong downtrend. Immediate support is located at $1.08, while resistance sits at $1.30.
Market Sentiment: PALI scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.90 (+660.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PALI is in a strong downtrend. Immediate support is located at $1.08, while resistance sits at $1.30.
Market Sentiment: PALI scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.90 (+660.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.18 -
$1.47
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
Trading Range & Key Levels
30-Day Trading Range
$1.18 -
$1.47
Current vs Trading Range
OVERSOLD
Support Level
$1.08
Resistance Level
$1.30
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 660.7% below Wall St target ($8.90)
- CAUTION: Bottoming setup, but lagging the sector by 15% over 20 days — wait for relative strength
Fundamental Context
Forward P/E (Next Year Est.)
-4.12
Wall Street Target
$8.90
(+660.7%)
Share PALI Analysis
Share this live PALI analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PALI)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 12, 2026
Daily AI digest
AI Retail Discussion Summary:
Investor bullish on $PALI following presentation of new clinical, pharmacokinetic, pharmacodynamic, and mechanistic data supporting Phase 2 trial of PALI-2108 in ulcerative colitis and Crohn's disease at ACG 2026.
Key Retail Themes:
Positive clinical trial data
Advancement in Phase 2 trial of PALI-2108
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:29 PM ET
Data refreshes hourly during market hours. Next update: 3:29 PM
Data refreshes hourly during market hours. Next update: 3:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PALI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 50 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$64 | 48 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 42 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PALI Research Pages
